Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49,741 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neoplastic Syndrome Clear all
Recruiting Phase 2 Interventional

Acupuncture for People Experiencing Period Loss Due to Chemotherapy

NCT06915116
View directory record Official record
Conditions
Cancer, Period Problem
Interventions
Acupuncture, No Acupuncture
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Active, not recruiting No phase listed Observational

Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers

NCT02041416
View directory record Official record
Conditions
Cancer, Solid Tumor, Hematologic Malignancy
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

NCT03498716
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Concord, California • Los Angeles, California • St. Helena, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 20, 2026, 6:40 PM EDT
Active, not recruiting Early Phase 1 Interventional

SBRT + Atezolizumab + Bevacizumab in Resectable HCC

NCT04857684
View directory record Official record
Conditions
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Stereotactic Beam Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Energy Balance Interventions for Colorectal Cancer Prevention

NCT00653484
View directory record Official record
Conditions
Colorectal Cancer, Obesity
Interventions
Physical Activity, Energy Restriction, Physical Activity and Energy Restriction
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Jul 20, 2026, 6:40 PM EDT
Completed No phase listed Observational Results available

Safety of Pregnancy in BRCA Mutated Breast Cancer Patients

NCT03673306
View directory record Official record
Conditions
Breast Cancer
Interventions
Clinical outcomes
Other
Lead sponsor
Jules Bordet Institute
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
4,732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
New Haven, Connecticut • Boston, Massachusetts • Lansing, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

NCT02348216
View directory record Official record
Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
Interventions
Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Early Phase 1 Interventional

PET and MRI Imaging of Brain Tumors Using [18F]PARPi

NCT04173104
View directory record Official record
Conditions
Brain Tumor, Brain Cancer
Interventions
PET/MR with [18F]PARPi, [18F]PARPi
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting No phase listed Observational

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

NCT06551116
View directory record Official record
Conditions
HER2-positive Metastatic Breast Cancer
Interventions
CE-10-IVD
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
37
States / cities
San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Not listed Phase 2 Interventional

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

NCT00423306
View directory record Official record
Conditions
HEPATOCELLULAR CARCINOMA
Interventions
Darinaparsin
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma

NCT00002314
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Ro 24-7429
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 20, 2026, 6:40 PM EDT
Completed No phase listed Observational

Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer

NCT05399004
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Survey Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Iowa City, Iowa • Lafayette, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)

NCT02447887
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, RCC
Interventions
Ixazomib, Pegylated IFN-alpha 2b
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Jul 20, 2026, 6:40 PM EDT
Withdrawn Phase 2 Interventional

Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

NCT02628704
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Placebo (for selinexor), carfilzomib, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
West Hollywood, California • Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

NCT00325416
View directory record Official record
Conditions
Multiple Myeloma
Interventions
melphalan, topotecan (TPT), Autologous Stem Cell Rescue
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 20, 2026, 6:40 PM EDT
Active, not recruiting Phase 1 Interventional

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804
View directory record Official record
Conditions
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Interventions
zongertinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Beverly Hills, California • Duarte, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated No phase listed Observational

Fertility Preservation- Oncology Treatment Effects and Psychological Impact

NCT02515916
View directory record Official record
Conditions
Cancer
Interventions
Not Interventional
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting Early Phase 1 Interventional

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

NCT04744116
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease
Interventions
Cellular Therapy, Ruxolitinib
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

NCT04479306
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Alisertib, Osimertinib, Sapanisertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

NCT05427214
View directory record Official record
Conditions
Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastric Cancer, Ovarian Cancer, Colon Cancer
Interventions
Halcyon 4.0 system
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 4 Interventional Results available

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

NCT03051516
View directory record Official record
Conditions
High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
27 Years to 69 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 20, 2026, 6:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806
View directory record Official record
Conditions
Multiple Myeloma
Interventions
idecabtagene vicleucel, Lenalidomide, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Active, not recruiting Phase 1 Interventional

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

NCT05413304
View directory record Official record
Conditions
Glioma
Interventions
pre-operative abemaciclib, Device for Cerebral Fluid Dialysate Collection, Ashion Analytics GEM ExTra, abemaciclib + temozolomide
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 39 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 1 Interventional

A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)

NCT05375604
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma (HCC), Gastric Cancer Metastatic to Liver, Colorectal Cancer Metastatic to Liver
Interventions
CDK-004
Drug
Lead sponsor
Codiak BioSciences
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Duarte, California • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Jul 20, 2026, 6:40 PM EDT